Gilead And Roche Resolve Tamiflu Licensing Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased antiviral demand in the face of seasonal flu and the threat of pandemic avian flu leads the firms to settle arbitration over a manufacturing and commercialization agreement.
You may also be interested in...
Gilead Acquisition Of Corus Adds Respiratory Disease Candidate
Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.
Gilead Acquisition Of Corus Adds Respiratory Disease Candidate
Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.
Gilead Files To Break Tamiflu Agreement With Roche, Citing Breach Of Contract
Roche will have a chance to address Gilead's claims before their partnership for the flu antiviral is terminated. Gilead claims Roche breached the contract by lessening its marketing efforts, neglecting manufacturing quality management, and inaccurately calculating royalty payments.